#co-pay

This ruling will affect millions and erect barriers to care, say patient advocacy groups representing those with cancer, HIV and more.

The Texas ruling builds on a case in which a plaintiff objected, on religious grounds, to providing free HIV prevention PrEP to employees.

The ruling centered on PrEP as HIV prevention but could apply to cancer screenings and other services and drugs.

Insurers should allow co-pay assistance to count as out-of-pocket spending, claims HHS lawsuit by HIV, hepatitis and diabetes advocates.

Some 100 million people—including 41% of U.S. adults—have health care debt, according to a recent KFF survey.

A letter from 124 patient groups urges the White House to make drugs more affordable—and spells out how it can do so.

During the COVID-19 crisis, some insurers are relaxing their refill rules and allowing 90-day supplies of meds to be prescribed.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Insurance companies can no longer implement harmful co-pay accumulator policies.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

Stop me if you’ve heard this one before.

The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.

Health coalition warns the federal government: People with chronic or serious conditions face growing costs at the pharmacy.

60 groups sign a letter to state insurance commissioners and attorneys general asking them to reverse the policy.

Cost concerns have led many private insurers and public payers to impose restrictions on treatment.